Cardiovascular DiseaseNCT00378924
Cardiology Biobank Registry
An observational study of Cardiovascular Disease, run by Emory University at 1 site in United States.
Trial summary
In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown… Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Disease
- How many people
- 12,000 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2003to Apr 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: General population \& patients presenting to the hospital
Who may be able to join
- All hospital and clinic participants aged 18 years and older
- Participants with and without active or presumed cardiovascular disease including but not limited to:
- Coronary Artery Disease
- Heart Failure and Cardiomyopathies
- Peripheral Vascular Disease
- Valve disease
Show all 9Show fewer
- Adult Congenital Heart disease
- Electrophysiological Disorders
- Any individual aged 18 and above in satisfactory physical health and able to tolerate a blood draw or buccal swab.
Who cannot join
- Significant Documented Anemia (Hemoglobin <8 g/dL)
- Blood transfusions within past 3 weeks
- Enrollment against doctor recommendation
- Participant not able to provide consent including but not limited to:
- Intubated and critically unwell participants
- Dementia
Show all 9Show fewer
- Alzheimer's disease
- Moderate to severe alcohol or drug abuse
- Against religious beliefs (e.g. Jehovah's witness)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Emory School Of Medicine
Atlanta, Georgia, 30322
Ayman J Tahhan, MD, 404 712 0168, ayman.tahhan@emory.edu
Salman Sher, MD, 404 712 0170, ssher2@emory.edu
About this study
In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized/Planned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers.
Once the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help us to understand how these diseases can be treated more effectively.
By collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.
Read the detailed description
Over the last several decades, scientists have made great progress in their understanding of cardiovascular disease. Nevertheless, much remains to be learned about the causes, course, and treatment of cardiovascular disease. In order to learn more about this topic, it is important to establish large databases of cardiovascular patients. These databases allows scientists to investigate, in a rigorous and precise manner, those factors that influence cardiovascular disease.
In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized/Planned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers.
Investigators will collect a large amount of data on these patients. Data to be collected will include information on:
Medical record data, including imaging Patient questionnaire data DNA and other biochemical data obtained and/or generated from patient blood samples or cheek (buccal) swabs Non-invasive measurements of blood pressure, heart rate and studies relating to assessment of the health of arteries
The data noted above will be collected by:
administering questionnaires/interviews to the patients accessing the medical records of the patients collecting blood samples from patients which will be analyzed by laboratories for their biochemical content.
Once the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help investigators to understand how these diseases can be treated more effectively.
How the Research Will Advance Scientific Knowledge/Human Health:
By collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.
- Conditions
- Cardiovascular Disease
- Medical subject headings
- Cardiovascular Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
All cause death
Measured: Continuous
Secondary outcomes (2)
Cardiovascular death
Measured: Continuous
Re-hospitalization for heart failure
Measured: Continuous
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2006 (estimated)
- Study startDec 2003
- Primary completionApr 2030 (estimated)
- Study completionApr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 12,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Arshed A. Quyyumi, Emory University
- Investigators
- Arshed A Quyyumi, MD, Principal investigator, Emory School Of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00378924
- Sponsor's protocol ID
- IRB00000343
- Other IDs
- 950-2003, 2025P011265
- Status last verified
- Jun 2026
- First submitted
- 19 Sep 2006
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiology Biobank Registry
- ClinicalTrials.gov ID
- NCT00378924
- Acronym / sponsor ID
- IRB00000343
- Conditions
- Cardiovascular Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 12,000 participants (estimated)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Study start
- Dec 2003
- Primary completion
- Apr 2030 (estimated)
- Study completion
- Apr 2030 (estimated)
- First posted
- 21 Sep 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized/Planned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers.
Once the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help us to understand how these diseases can be treated more effectively.
By collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.
Detailed description
Over the last several decades, scientists have made great progress in their understanding of cardiovascular disease. Nevertheless, much remains to be learned about the causes, course, and treatment of cardiovascular disease. In order to learn more about this topic, it is important to establish large databases of cardiovascular patients. These databases allows scientists to investigate, in a rigorous and precise manner, those factors that influence cardiovascular disease.
In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized/Planned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers.
Investigators will collect a large amount of data on these patients. Data to be collected will include information on:
Medical record data, including imaging Patient questionnaire data DNA and other biochemical data obtained and/or generated from patient blood samples or cheek (buccal) swabs Non-invasive measurements of blood pressure, heart rate and studies relating to assessment of the health of arteries
The data noted above will be collected by:
administering questionnaires/interviews to the patients accessing the medical records of the patients collecting blood samples from patients which will be analyzed by laboratories for their biochemical content.
Once the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help investigators to understand how these diseases can be treated more effectively.
How the Research Will Advance Scientific Knowledge/Human Health:
By collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- General population \& patients presenting to the hospital
Key inclusion criteria (9 listed)
- All hospital and clinic participants aged 18 years and older
- Participants with and without active or presumed cardiovascular disease including but not limited to:
- Any individual aged 18 and above in satisfactory physical health and able to tolerate a blood draw or buccal swab.
Key exclusion criteria (9 listed)
- Significant Documented Anemia (Hemoglobin <8 g/dL)
- Blood transfusions within past 3 weeks
- Enrollment against doctor recommendation
- Participant not able to provide consent including but not limited to:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
All cause death
Time frame: Continuous
2 secondary outcomes
Cardiovascular death
Time frame: Continuous
Re-hospitalization for heart failure
Time frame: Continuous
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
Related trials for Cardiovascular Disease
Not yet recruiting
Brain-Machine Interface With Virtual Reality and Neuromuscular Electrical Stimulation for Upper Limb Rehabilitation After Stroke
Ischemic Stroke
Not yet recruitingPhase 4
An Investigator-initiated, Prospective, Open-label, Multicenter Randomized Controlled Trial, Comparing the Efficacy of Sacubitril/Valsartan and Standard Treatment on Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients Without Hypertensive
Atrial Fibrillation (Persistent), Catheter Ablation
Not yet recruiting
LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI
TAVI(Transcatheter Aortic Valve Implantation), Left Bundle Branch Block
Recruiting
Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
Severe Tricuspid Valve Regurgitation, Tricuspid Valve Regurgitation
Recruiting
Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial
Dyslipidemias, Atherosclerotic Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Arshed A Quyyumi, MD principal investigator
Emory School Of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Disease, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ayman J Tahhan, MD (404 712 0168, ayman.tahhan@emory.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All cause death (time frame: Continuous). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.